

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jenscare Scientific Co., Ltd.**  
**寧波健世科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9877)**

**VOLUNTARY ANNOUNCEMENT**

**EARLY FEASIBILITY STUDY OF LUX-VALVE PLUS  
PRE-SUBMISSION ACCEPTED BY THE FDA**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business updates and new product development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that the Group has submitted a pre-submission for the early feasibility study (EFS) of LuX-Valve Plus, which has been officially accepted by the Food and Drug Administration of the United States (“**FDA**”). The preparation of LuX-Valve Plus’s Investigational Device Exemption (IDE) application in the United States has officially commenced. It marks the significant progress made by LuX-Valve Plus in the United States clinical trial registration process and in overseas business expansion.

The Group will continue to promote the global clinical and commercial activities of its transcatheter tricuspid valve replacement products, so as to benefit the huge market of tricuspid regurgitation patients.

**Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**Jenscare Scientific Co., Ltd.**  
**Mr. LV Shiwen**  
*Chairman and Executive Director*

Hong Kong, July 7, 2023

*As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.*